Oregon Translational Research Anddrug Development Institute

Is Oregon Translational Research Anddrug Development Institute Legit?

Some Concerns

Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →

Oregon Translational Research Anddrug Development Institute directs 80% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.

About Oregon Translational Research Anddrug Development Institute

Oregon Translational Research Anddrug Development Institute (EIN: 208877231) is a nonprofit organization based in Portland, OR, classified under NTEE code B19. The organization reported total revenue of $2.5M and total assets of $15.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Oregon Translational Research Anddrug Development Institute's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

Organization Overview

Oregon Translational Research Anddrug Development Institute is a mid-size nonprofit that has been operating for 18 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 2.2%.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

Financial Health Grade: C

In 2023, Oregon Translational Research Anddrug Development Institute reported a deficit of $211K with expenses exceeding revenue, holds 95.2 months of operating reserves (strong position), has a debt-to-asset ratio of 73.1% (high leverage).

Financial Trends

Over 13 years of filings (2011–2023), Oregon Translational Research Anddrug Development Institute's revenue has grown at a compound annual growth rate (CAGR) of 2.2%.

IRS Tax-Exempt Classification

Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.

AI Transparency Report

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Oregon Translational Research Anddrug Development Institute with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

• admin: 15%
• programs: 80%
• fundraising: 5%

According to IRS 990 filings, Oregon Translational Research Anddrug Development Institute allocates its expenses as follows: admin: 15%, programs: 80%, fundraising: 5%. With 80% directed toward programs, this reflects a strong commitment to its charitable mission.

Key Financial Metrics (2023)

From the most recent IRS 990 filing on record:

• The organization reported a deficit of $211K, with expenses exceeding revenue.
• Debt-to-asset ratio: 73.1%.

Executive Compensation Analysis

The organization consistently reports 0% officer compensation across all available filings, indicating that no salaries or benefits were paid to officers, which is highly unusual for an organization of its size with over $2 million in annual revenue and $16 million in assets. This suggests either a volunteer-led executive structure or that executive compensation is reported under other expense categories, warranting further investigation for complete transparency.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Oregon Translational Research Anddrug Development Institute's IRS 990 filings:

• Significant increase in liabilities from $715,041 in 2020 to $11,822,092 in 2023 without clear explanation in summary data.
• 0% reported officer compensation for an organization of this size and asset level, which is highly unusual and may obscure actual executive remuneration if reported elsewhere.

Strengths

The following positive indicators were identified for Oregon Translational Research Anddrug Development Institute:

• Strong asset growth from $4.1 million in 2020 to $16.1 million in 2023, indicating financial health and capacity.
• Consistent revenue generation, generally exceeding expenses in recent years, demonstrating operational sustainability.
• Long filing history (13 filings) indicates consistent compliance and reporting.

Frequently Asked Questions about Oregon Translational Research Anddrug Development Institute

Filing History

IRS 990 filing history for Oregon Translational Research Anddrug Development Institute showing financial trends over 13 years of public records:

Over 13 years of IRS 990 filings (2011–2023), Oregon Translational Research Anddrug Development Institute's revenue has grown by 29.1%, moving from $1.4M to $1.8M. Total assets increased by 286.4% over the same period, from $4.2M to $16.2M. Total functional expenses rose by 43.3%, from $1.4M to $2.0M. In its most recent filing year (2023), Oregon Translational Research Anddrug Development Institute reported a deficit of $211K, with expenses exceeding revenue. The organization holds $11.8M in liabilities against $16.2M in assets (debt-to-asset ratio: 73.1%), resulting in net assets of $4.3M.

Year-by-Year Financial Summary

• 2023: Revenue of $1.8M, expenses of $2.0M, and assets of $16.2M (revenue -17.8% year-over-year).
• 2022: Revenue of $2.2M, expenses of $2.0M, and assets of $16.3M (revenue +8.9% year-over-year).
• 2021: Revenue of $2.0M, expenses of $1.7M, and assets of $6.2M (revenue +11.9% year-over-year).
• 2020: Revenue of $1.8M, expenses of $1.5M, and assets of $4.2M (revenue -5.0% year-over-year).
• 2019: Revenue of $1.9M, expenses of $1.6M, and assets of $5.1M (revenue +6.4% year-over-year).
• 2018: Revenue of $1.8M, expenses of $1.6M, and assets of $3.7M (revenue +11.6% year-over-year).
• 2017: Revenue of $1.6M, expenses of $1.6M, and assets of $4.7M (revenue -14.1% year-over-year).
• 2016: Revenue of $1.9M, expenses of $1.9M, and assets of $3.5M (revenue +30.6% year-over-year).
• 2015: Revenue of $1.4M, expenses of $1.9M, and assets of $4.9M (revenue -3.1% year-over-year).
• 2014: Revenue of $1.5M, expenses of $1.5M, and assets of $4.4M (revenue +0.9% year-over-year).
• 2013: Revenue of $1.5M, expenses of $1.9M, and assets of $4.7M (revenue -0.4% year-over-year).
• 2012: Revenue of $1.5M, expenses of $1.4M, and assets of $4.2M (revenue +4.6% year-over-year).
• 2011: Revenue of $1.4M, expenses of $1.4M, and assets of $4.2M.

View Individual Filing Years

Explore detailed financial data from each IRS 990 filing year for Oregon Translational Research Anddrug Development Institute:

Data Sources and Methodology

This transparency report for Oregon Translational Research Anddrug Development Institute is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.